Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis

• DOI: 10.1007/s13277-015-3534-8
• Publication Date: 2015-06-04T22:41:27Z
• Authors: Hong-Xing Li; Wei Zhao; Yan Shi; Ya-Na Li; Lian-Shuang Zhang; Hong-Qin Zhang; Dong Wang
• Keywords: Lung Neoplasms; Apoptosis; Tretinoin; Amides; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays; Neoplasm Proteins; 3. Good health; Mice; STAT Transcription Factors; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Animals; Humans; M Phase Cell Cycle Checkpoints; Cell Proliferation; Signal Transduction

Small cell lung cancer (SCLC) accounts for 12 to 16% of lung neoplasms and has a high rate of metastasis. The present study demonstrates the antiproliferative effect of retinoic acid amide in vitro and in vivo against human lung cancer cells. The results from MTT assay showed a significant growth inhibition of six tested lung cancer cell lines and inhibition of clonogenic growth at 30 μM. Retinoic acid amide also leads to G2/M-phase cell cycle arrest and apoptosis of lung cancer cells. It caused inhibition of JAK2, STAT3, and STAT5, increased the level of p21WAF1, and decreased cyclin A, cyclin B1, and Bcl-XL expression. Retinoic acid amide exhibited a synergistic effect on antiproliferative effects of methotrexate in lung cancer cells. In lung tumor xenografts, the tumor volume was decreased by 82.4% compared to controls. The retinoic acid amide-treated tumors showed inhibition of JAK2/STAT3 activation and Bcl-XL expression. There was also increase in expression of caspase-3 and caspase-9 in tumors on treatment with retinoic acid amide. Thus, retinoic acid amide exhibits promising antiproliferative effects against human lung cancer cells in vitro and in vivo and enhances the antiproliferative effect of methotrexate.